Cover Image
市場調查報告書

Cerenis Therapeutics Holding SA:產品平台分析

Cerenis Therapeutics Holding SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 333711
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
Cerenis Therapeutics Holding SA:產品平台分析 Cerenis Therapeutics Holding SA - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 31 Pages
簡介

Cerenis Therapeutics Holding SA,是從事針對治療心血管疾病,代謝性疾病的HDL療法之藥物研發·開發的製藥公司。

本報告提供Cerenis Therapeutics Holding SA之調查分析,提供您治療藥的開發平台最新資訊,加上各開發階段比較分析,藥物標的·作用機制·給藥途徑·各分子類型的治療藥評估,也包含最新消息和新聞稿,後期階段·中止的計劃等系統性資訊。

目錄

Cerenis Therapeutics Holding SA的基本資料

  • Cerenis Therapeutics Holding SA概要
  • 主要資訊
  • 企業資料

Cerenis Therapeutics Holding SA:研究開發概要

  • 主要的治療領域

Cerenis Therapeutics Holding SA:開發平台檢驗

  • 開發中產品:各開發階段
  • 開發中產品:單獨療法
  • 開發中產品:聯合治療
  • 開發中產品:合作夥伴產品

Cerenis Therapeutics Holding SA:開發中產品的概要

  • 臨床階段的開發中產品
  • 初期階段的開發中產品

Cerenis Therapeutics Holding SA:藥物簡介

  • (niacin + aspirin)
  • CER-001
  • CER-522
  • NC-2400
  • (statin + niacin + aspirin)
  • CER-209

Cerenis Therapeutics Holding SA:開發平台分析

  • 開發中產品:標的別
  • 開發中產品:各給藥途徑
  • 開發中產品:各分子類型
  • 開發中產品:各作用機制

Cerenis Therapeutics Holding SA:開發平台的最新趨勢

Cerenis Therapeutics Holding SA:暫停中的計劃

Cerenis Therapeutics Holding SA:所在地與子公司

附錄

目錄
Product Code: GMDHC07121CDB

Summary

Global Markets Direct's, 'Cerenis Therapeutics Holding SA - Product Pipeline Review - 2015', provides an overview of the Cerenis Therapeutics Holding SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cerenis Therapeutics Holding SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cerenis Therapeutics Holding SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cerenis Therapeutics Holding SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cerenis Therapeutics Holding SA's pipeline products

Reasons to buy

  • Evaluate Cerenis Therapeutics Holding SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cerenis Therapeutics Holding SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cerenis Therapeutics Holding SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cerenis Therapeutics Holding SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cerenis Therapeutics Holding SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cerenis Therapeutics Holding SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cerenis Therapeutics Holding SA Snapshot
    • Cerenis Therapeutics Holding SA Overview
    • Key Information
    • Key Facts
  • Cerenis Therapeutics Holding SA - Research and Development Overview
    • Key Therapeutic Areas
  • Cerenis Therapeutics Holding SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Cerenis Therapeutics Holding SA - Pipeline Products Glance
    • Cerenis Therapeutics Holding SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Cerenis Therapeutics Holding SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Cerenis Therapeutics Holding SA - Drug Profiles
    • (niacin + aspirin)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CER-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CER-522
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NC-2400
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (statin + niacin + aspirin)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CER-209
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cerenis Therapeutics Holding SA - Pipeline Analysis
    • Cerenis Therapeutics Holding SA - Pipeline Products by Target
    • Cerenis Therapeutics Holding SA - Pipeline Products by Route of Administration
    • Cerenis Therapeutics Holding SA - Pipeline Products by Molecule Type
    • Cerenis Therapeutics Holding SA - Pipeline Products by Mechanism of Action
  • Cerenis Therapeutics Holding SA - Recent Pipeline Updates
  • Cerenis Therapeutics Holding SA - Dormant Projects
  • Cerenis Therapeutics Holding SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cerenis Therapeutics Holding SA, Key Information
  • Cerenis Therapeutics Holding SA, Key Facts
  • Cerenis Therapeutics Holding SA - Pipeline by Indication, 2015
  • Cerenis Therapeutics Holding SA - Pipeline by Stage of Development, 2015
  • Cerenis Therapeutics Holding SA - Monotherapy Products in Pipeline, 2015
  • Cerenis Therapeutics Holding SA - Combination Treatment Modalities in Pipeline, 2015
  • Cerenis Therapeutics Holding SA - Partnered Products in Pipeline, 2015
  • Cerenis Therapeutics Holding SA - Partnered Products/ Combination Treatment Modalities, 2015
  • Cerenis Therapeutics Holding SA - Phase II, 2015
  • Cerenis Therapeutics Holding SA - Phase I, 2015
  • Cerenis Therapeutics Holding SA - Preclinical, 2015
  • Cerenis Therapeutics Holding SA - Pipeline by Target, 2015
  • Cerenis Therapeutics Holding SA - Pipeline by Route of Administration, 2015
  • Cerenis Therapeutics Holding SA - Pipeline by Molecule Type, 2015
  • Cerenis Therapeutics Holding SA - Pipeline Products by Mechanism of Action, 2015
  • Cerenis Therapeutics Holding SA - Recent Pipeline Updates, 2015
  • Cerenis Therapeutics Holding SA - Dormant Developmental Projects,2015
  • Cerenis Therapeutics Holding SA, Other Locations

List of Figures

  • Cerenis Therapeutics Holding SA - Pipeline by Top 10 Indication, 2015
  • Cerenis Therapeutics Holding SA - Pipeline by Stage of Development, 2015
  • Cerenis Therapeutics Holding SA - Monotherapy Products in Pipeline, 2015
  • Cerenis Therapeutics Holding SA - Combination Treatment Modalities in Pipeline, 2015
  • Cerenis Therapeutics Holding SA - Pipeline by Top 10 Target, 2015
  • Cerenis Therapeutics Holding SA - Pipeline by Top 10 Route of Administration, 2015
  • Cerenis Therapeutics Holding SA - Pipeline by Top 10 Molecule Type, 2015
  • Cerenis Therapeutics Holding SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top